Indivumed, Definiens Partner
News Jul 20, 2016
Definiens and Indivumed have announced a strategic partnership to offer a unique combination of tissue-based biomarker validation and assay development with Definiens Cognition Network Technology® for image analysis and data mining.
This partnership will allow researchers and clinicians in oncology to benefit from a joint offering of Indivumed’s leading Cancer Database, Biobank and analytical laboratory services for tissue analysis together with Definiens’ leading proprietary Cognition Network Technology® and the Tissue Phenomics® approach to oncology and diagnostics.
Indivumed specializes in stringent and highly standardized tissue collection processes that preserve biomolecules such as RNA and protein, allowing more accurate assessment of tissue patterns and more rigorous comparisons across samples. “Customers of either company can now benefit from this partnership and our comprehensive approach for image analysis and tissue-based research and development in oncology,” said Hartmut Juhl, Founder and Chief Executive Officer, Indivumed.
“In the quest to use tissue biomarkers to create diagnostic tests for cancer patients, there is no question that the quality of tissue combined with advanced image analysis and tissue mining is extremely important,” commented Ralf Huss, Chief Medical Officer, Definiens.
“This partnership allows researchers and clinicians to benefit from the expertise of both our companies and advance personalized medicine for the treatment of patients. It will be great to see this partnership benefit not only researchers and clinicians, but also ultimately cancer patients.”
Putting Proteins in Their Proper PlaceNews
Everything in the cell has its right place. This includes certain molecules called RNA-binding proteins. When these are misplaced, they can end up causing dangerous clumps that are typical of diseases like ALS. A new study has found a way to send these proteins home.READ MORE
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE
Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug ScreeningNews
A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018